Clinical trials – Stem cells and Autism
| Type of trial | Number and type of cells transplanted/source | Duration | Primary outcomes | Reference |
|---|---|---|---|---|
| Autologous, open-label | 8.19 × 107 mononuclear cells/bone marrow | 26 months | Safety Improvements in cognitive and social tasks Improvement in hypoperfused brain areas | 88 |
| Allogenic, nonrandomized, open-label, single-center Phase I/II trial, combined transplantation | 2 × 106/kg mononuclear cells/cord blood and 1 × 106/kg mesenchymal stem cells/umbilical cord | 24 weeks | Safety Improvements in stereotypic behaviors and lethargy/social withdrawal | 91 |
| Allogenic, open-label, single center | 30 × 106/mL fetal stem cells/fetus | 12 months | Safety Improvement in cognitive ability, behaviors, sociabilityImprovements in immune functions | 37 |
| Autologous, randomized, blinded, placebo- controlled | Umbilical cord | 24 weeks | Safety No improvements in symptoms | 93 |
| Autologous, Phase I, single-center, open-label | Umbilical cord | 12 months | Safety Improvement in socialization, communication, and adaptive behavior | 94 |
Interested in learning whether current clinical programs, research developments, or emerging therapeutic approaches may be relevant to your situation?
Educational and research information only. Individual medical decisions should be made in consultation with qualified healthcare professionals.
